卫信康股价震荡，集采政策或影响行业格局

Core Viewpoint - The stock price of Weixin Kang (卫信康) has shown a fluctuating trend over the past week, with a range of 0.27% and an amplitude of 2.14% [1] Group 1: Stock Performance - As of February 12, the closing price was 11.26 yuan, down 1.14% for the day, with a trading volume of 14.43 million yuan [1] - On February 11, the closing price was 11.39 yuan, reflecting a decrease of 0.35% [1] - Over the past five days, there has been a net outflow of 1.1653 million yuan in main funds, while on February 11, there was a net inflow of 115,100 yuan [1] Group 2: Recent Events - On February 9, 2026, a national drug procurement process was initiated, involving 316 commonly used drugs, which may impact the overall competitive landscape of the pharmaceutical industry until the end of 2028 [2] - Weixin Kang has no significant new events recently, but its calcium gluconate injection has passed the consistency evaluation for generic drugs, expected by December 2024 [2] Group 3: Financial Report Analysis - The third-quarter report for 2025 indicates that Weixin Kang's revenue for the first three quarters was 862 million yuan, a year-on-year decrease of 13.27% [3] - The net profit attributable to the parent company was 219 million yuan, down 9.90% year-on-year [3] Group 4: Institutional Perspectives - Institutions have set a comprehensive target price of 15.20 yuan for Weixin Kang, indicating a potential upside of approximately 34.99% from the latest price [4] - Current market sentiment is neutral, with low frequency of institutional research, while profit forecasts suggest a projected net profit growth of 25.93% for 2026 [4]